The drug-delivery technology that enables Bydureon to be dosed so infrequently comes from Alkermes (ALKS), which will receive royalties on sales of the drug when approved.
Bydureon and Novo Nordisk's (NVO) recently approved Victoza belong to the GLP-1 class of injectable diabetes drugs intended to control blood sugar in Type 2 diabetes medicines. Victoza requires a once-daily injection.
Amylin shares closed Friday at $20.26; Alkermes shares closed at $12.21.
-- Reported by Adam Feuerstein in Boston.Follow Adam Feuerstein on Twitter.